Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mucus-Targeting inhaler tested for lung disease – study stopped early

NCT ID NCT05292950

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 33 times

Summary

This study tested an inhaled drug called ARO-MUC5AC in healthy people and those with asthma or COPD. The goal was to see if it was safe and could improve lung function by reducing mucus. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site 1

    Nedlands, 6009, Australia

  • Research Site 1

    Auckland, 1010, New Zealand

  • Research Site 1

    Bialystok, 15-010, Poland

  • Research Site 1

    Seoul, 04763, South Korea

  • Research Site 1

    Barcelona, 08017, Spain

  • Research Site 1

    Bangkok, 10700, Thailand

  • Research Site 1

    Wythenshawe, Manchester, M23 9QZ, United Kingdom

  • Research Site 2

    South Brisbane, Queensland, 4101, Australia

  • Research Site 2

    Auckland, 1051, New Zealand

  • Research Site 2

    Krakow, 31-455, Poland

  • Research Site 2

    Jeonju, 54907, South Korea

  • Research Site 3

    Oświęcim, 32-600, Poland

  • Research Site 3

    Bucheon-si, Gyeonggi-do, 14647, South Korea

Conditions

Explore the condition pages connected to this study.